TrialThe Lancet. Oncology2016

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Fred Saad et al.PubMed ↗Publisher ↗

No numbers read from the abstract.